

EU (MA) number	Invented name	Strength	Pharmaceutical form	Target species	Route of administration	Packaging	Content	Package size	Withdrawal period
EU/2/14/173/001	Versican Plus Pi/L4R	--1	Lyophilisate and suspension for suspension for injection	Dogs	Subcutaneous use	Lyophilisate: vial (glass) Suspension: vial (glass)	Lyophilisate: 1 dose + Suspension: 1 ml	Lyophilisate: 25 vials + suspension: 25 vials	Not applicable
EU/2/14/173/002	Versican Plus Pi/L4R	--1	Lyophilisate and suspension for suspension for injection	Dogs	Subcutaneous use	Lyophilisate: vial (glass) Suspension: vial (glass)	Lyophilisate: 1 dose + Suspension: 1 ml	Lyophilisate: 50 vials + suspension: 50 vials	Not applicable

--1 Lyophilisate (live attenuated)

Canine parainfluenza type 2 virus, strain CPiV-2 Bio 15

$10^{3.1} - 10^{5.1}$  TCID<sub>50</sub>\*

I Suspension (inactivated)

*Leptospira interrogans* serogroup Icterohaemorrhagiae

serovar Icterohaemorrhagiae strain MSLB 1089

ALR\*\* titre  $\geq$  1:51

*Leptospira interrogans* serogroup Canicola

serovar Canicola, strain MSLB 1090

ALR\*\* titre  $\geq$  1:51

*Leptospira kirschneri* serogroup Grippotyphosa

serovar Grippotyphosa, strain MSLB 1091

ALR\*\* titre  $\geq$  1:40

*Leptospira interrogans* serogroup Australis

serovar Bratislava, strain MSLB 1088

ALR\*\* titre  $\geq$  1:51

Rabies virus, strain SAD Vnukovo-32

$\geq 2.0$  IU\*\*\*

\* Tissue culture infectious dose 50%.

\*\* Antibody micro agglutination-lytic reaction.

\*\*\* International units.